Ahmed Z, Kennedy K, Subramanian J., et al. - Among patients ≥ 80 years old suffering from advanced non-small cell lung carcinoma (NSCLC), treatment patterns as well as outcomes were analyzed using the National Cancer Database. For 33,352 advanced NSCLC patients > 80 years old, data were obtained on median age at diagnosis, gender, ethnicity, histology, chemotherapy status, tumor grade, treatment center, insurance status, income, education, and Charlson-Deyo co-morbidity index. Chemotherapy was received by only 29% of these patients. Chemotherapy was beneficial for all age subgroups (80 - 84 years, 85 - 89 years and 90+ years), as shown in multivariable analysis, and propensity matched analysis also corroborated this finding. Improved 1-year survival of 35.5% was achieved with multiagent chemotherapy vs 32.8% with single agent chemotherapy. Findings showed that improved overall survival was conferred by chemotherapy in patients ≥ 80 years old suffering from advanced stage NSCLC. Chemotherapy was received by less than one-third, despite improved survival and more patients ≥ 80 years old being diagnosed with advanced NSCLC.